Table 2

HPV results in mothers and infants included in the prospective cohort study.

Number

(n = 143)

%

(95% CI)


Mothers' HPV-DNA status at pregnancy

Positive/Tested

66/143

46.2

(37.8–54.7)

Type distribution among HPV positive:

HPV 6,11

10

15.2

HPV 16

17

25.8

HPV 18

4

6.1

HPV 31

1

1.5

HPV 33

1

1.5

HPV 39

1

1.5

HPV 16 + other types

7

10.6

HPV 31 + other types

5

7.6

HPV 33 + other types

1

1.5

HPV X

19

28.8

Mothers' HPV-DNA prevalence at 6 weeks postpartum

Positive/Tested

25/118

21.2

(14.2–29.7)

Type distribution among HPV positive:

HPV 6,11

4

16.0

HPV 16

8

32.0

HPV 18

2

8.0

HPV 16 + other types

2

8.0

HPV 18 + other types

1

4.0

HPV 31 + other types

2

8.0

HPV 39 + other types

1

4.0

HPV X

5

20.0

Infants' HPV-DNA positivity (positive/tested)

Between 0 and 6 days

7/117

6.0

(2.4–11.9)

6 weeks after birth

14/110

12.7

(7.1–20.4)

Between 3 and 24 months

8/88

9.1

(4.0–17.1)

At any point (0 to 24 months)

26/143

18.2

(12.2–25.5)

Type distribution among HPV positive (at any point during follow-up):

HPV X

10

38.5

HPV 16

8

30.8

HPV 6/11

6

23.1

HPV 18

1

3.8

HPV 31

1

3.8

Infants' HPV positivity by mother's HPV-DNA status (positive/tested)

Born to HPV negative mothers

13/77

16.9

(9.3–27.1)

Born to HPV positive mothers

13/66

19.7

(10.9–31.3)

Origin of HPV positive samples in children

Oral

16

51.6

Genital

15

48.4


Castellsagué et al. BMC Infectious Diseases 2009 9:74   doi:10.1186/1471-2334-9-74

Open Data